Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group

Neuro-Oncology

Volumn 13, Issue 3, 2011, Pages 317-323

  Cohen, Kenneth J ^a   Pollack, Ian F ^b   Zhou, Tianni ^c,d   Buxton, Allen ^d   Holmes, Emiko J ^d   Burger, Peter C ^e   Brat, Daniel J ^f   Rosenblum, Marc K ^g   Hamilton, Ronald L ^b   Lavey, Robert S ^h   Heideman, Richard L ⁱ  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

High grade glioma; Pediatric brain tumors; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CHEMORADIOTHERAPY; CHILD; CRANIAL NEUROPATHY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRESCHOOL CHILD; RADIATION DOSE; SCHOOL CHILD; SEIZURE; SENSORY NEUROPATHY; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955453343     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq191     Document Type: Article

References (26)

1. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children's Cancer Group. J Clin Oncol. 1995; 13:112-123.
2. Boyett J, Yates A, Gilles F, et al. When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (OTH-HGA) by five neuropathologists. Proc Am Soc Clin Oncol. 1998; 17:526a.
3. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23:2372-2377. (Pubitemid 46218731)
4. Jalali R, Basu A, Gupta T, et al. Encouraging experience of concomitant temozolomide with radiotherapy followed by adjuvant temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Br J Neurosurg. 2007; 21:583-587. (Pubitemid 350249205)
5. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009; 27:3861-3867.
6. Jeon HJ, Kong DS, Park KB, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: single-center experience. Clin Neurol Neurosurg. 2009; 111:679-682.
7. van Genugten JA, Leffers P, Baumert BG, et al. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010; 96:249-257.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996. (Pubitemid 40349501)
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003. (Pubitemid 40349502)
10. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006; 105:418-424. (Pubitemid 44954773)
11. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
12. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343:1350-1354.
13. Pollack IF, Boyett JM, Yates AJ, et al. The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience. Neuro-Oncol. 2003; 5:197-207. (Pubitemid 36790349)
14. Cohen K, Aronson L, Siffert J, et al. Final outcome of a Phase 1 trial of low-dose temozolomide given concurrently with radiation therapy in children and adolescents with brain tumors. 2002; ISPNO Abstracts: O44.
15. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991; 39:741-748.
16. Brent TP, von Wronski M, Pegram CN, et al. Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. Cancer Res. 1990; 50:58-61. (Pubitemid 20029994)
17. McLendon RE, Cleveland L, Pegram C, et al. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest. 1998; 78:643-644. (Pubitemid 28246989)
18. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol. 2006; 24:3431-3437. (Pubitemid 46638900)
19. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29:577-580. (Pubitemid 11147380)
20. Woolson RF. Rank tests and a one-sample logrank test for comparing observed survival data to a standard population. Biometrics. 1981; 37:687-696.
21. Sposto R. Cure model analysis in cancer: An application to data from the Children's Cancer Group. Stat Med. 2002; 21:293-312. (Pubitemid 34048694)
22. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002; 20:4684-4691. (Pubitemid 36025286)
23. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989; 7:165-177. (Pubitemid 19182070)
24. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26:4189-4199.
25. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol. 2010; 6:39-51.
26. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007; 48:403-407. (Pubitemid 46340105)